III期-话题@MedSci

#III期#

681篇内容 | 2800人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594687, encodeId=deec159468eb4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=LEO pharma的IL-13单抗在III期特应性皮炎临床研究中达到实验终点, objectType=article, longId=184948, objectId=7e421849487b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e421849487b, replyNumber=0, likeNumber=112, createdTime=2019-12-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e421849487b, moduleTitle=LEO pharma的IL-13单抗在III期特应性皮炎临床研究中达到实验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e421849487b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594686, encodeId=be011594686d2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, objectType=article, longId=184902, objectId=8f0518490243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f0518490243, replyNumber=0, likeNumber=76, createdTime=2019-12-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f0518490243, moduleTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f0518490243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594685, encodeId=346f159468599, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, objectType=article, longId=184569, objectId=5a93184569d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a93184569d3, replyNumber=0, likeNumber=13, createdTime=2019-12-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a93184569d3, moduleTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a93184569d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594684, encodeId=ec481594684bb, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功, objectType=article, longId=184494, objectId=2df618449455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2df618449455, replyNumber=0, likeNumber=69, createdTime=2019-12-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2df618449455, moduleTitle=Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2df618449455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594683, encodeId=a781159468334, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=IMbrave 150：III期研究显示肝癌迎来治愈希望, objectType=article, longId=184473, objectId=124e1844e341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=124e1844e341, replyNumber=0, likeNumber=56, createdTime=2019-12-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=124e1844e341, moduleTitle=IMbrave 150：III期研究显示肝癌迎来治愈希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=124e1844e341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594682, encodeId=9999159468215, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, objectType=article, longId=184396, objectId=e1d618439611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1d618439611, replyNumber=0, likeNumber=0, createdTime=2019-12-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1d618439611, moduleTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1d618439611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594681, encodeId=5b311594681be, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, objectType=article, longId=184287, objectId=1a1218428e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a1218428e0d, replyNumber=0, likeNumber=13, createdTime=2019-12-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a1218428e0d, moduleTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a1218428e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594680, encodeId=eaaf159468079, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Ardelyx的实验性药物Tenapanor达到了高磷血症的第二个III期研究的主要目标, objectType=article, longId=184167, objectId=053a18416e94, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053a18416e94, replyNumber=0, likeNumber=67, createdTime=2019-12-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053a18416e94, moduleTitle=Ardelyx的实验性药物Tenapanor达到了高磷血症的第二个III期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=053a18416e94)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594679, encodeId=d4e215946e94f, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点, objectType=article, longId=183997, objectId=f31218399ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31218399ec7, replyNumber=0, likeNumber=97, createdTime=2019-12-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31218399ec7, moduleTitle=ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31218399ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594678, encodeId=f50915946e878, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：Satralizumab治疗视神经脊髓炎谱系疾病的SAkuraSky III期研究取得喜人结果, objectType=article, longId=183902, objectId=8908183902b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8908183902b8, replyNumber=0, likeNumber=14, createdTime=2019-12-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8908183902b8, moduleTitle=NEJM：Satralizumab治疗视神经脊髓炎谱系疾病的SAkuraSky III期研究取得喜人结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8908183902b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594677, encodeId=7c1615946e700, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=急性脑缺血性中风治疗：sovateltide（PMZ-1620）的III期关键性研究已经开始, objectType=article, longId=183569, objectId=a2d718356989, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2d718356989, replyNumber=0, likeNumber=55, createdTime=2019-11-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2d718356989, moduleTitle=急性脑缺血性中风治疗：sovateltide（PMZ-1620）的III期关键性研究已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2d718356989)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594676, encodeId=5a4815946e646, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=第68届ASTMH年会：登革热候选疫苗关键III期试验的18个月数据, objectType=article, longId=183562, objectId=963318356294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=963318356294, replyNumber=0, likeNumber=63, createdTime=2019-11-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=963318356294, moduleTitle=第68届ASTMH年会：登革热候选疫苗关键III期试验的18个月数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=963318356294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594675, encodeId=241a15946e5d3, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, objectType=article, longId=183554, objectId=f33d18355468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f33d18355468, replyNumber=0, likeNumber=14, createdTime=2019-11-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f33d18355468, moduleTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f33d18355468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594674, encodeId=492715946e4e9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, objectType=article, longId=183550, objectId=84a4183550aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84a4183550aa, replyNumber=0, likeNumber=11, createdTime=2019-11-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84a4183550aa, moduleTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84a4183550aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594673, encodeId=d5ea15946e386, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功, objectType=article, longId=183428, objectId=910418342888, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=910418342888, replyNumber=0, likeNumber=72, createdTime=2019-11-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=910418342888, moduleTitle=Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=910418342888)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594672, encodeId=7c1e15946e2b9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, objectType=article, longId=183195, objectId=6133183195fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6133183195fa, replyNumber=0, likeNumber=13, createdTime=2019-11-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6133183195fa, moduleTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6133183195fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594671, encodeId=401015946e1cd, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=吉利德的Vemlidy在III期研究中，可显著降低慢性乙型肝炎感染患者肝细胞癌的发生, objectType=article, longId=183120, objectId=cf0b18312019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0b18312019, replyNumber=0, likeNumber=53, createdTime=2019-11-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0b18312019, moduleTitle=吉利德的Vemlidy在III期研究中，可显著降低慢性乙型肝炎感染患者肝细胞癌的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0b18312019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594670, encodeId=dd5615946e0f2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=阿斯利康宣布其干扰素受体靶向单抗anifrolumab治疗系统性红斑狼疮的阳性III期结果, objectType=article, longId=183119, objectId=0eed183119e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0eed183119e8, replyNumber=0, likeNumber=75, createdTime=2019-11-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0eed183119e8, moduleTitle=阿斯利康宣布其干扰素受体靶向单抗anifrolumab治疗系统性红斑狼疮的阳性III期结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0eed183119e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594669, encodeId=81d51594669ac, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床, objectType=article, longId=182745, objectId=f0a2182e457c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0a2182e457c, replyNumber=0, likeNumber=68, createdTime=2019-11-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0a2182e457c, moduleTitle=ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0a2182e457c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594668, encodeId=841d159466804, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请, objectType=article, longId=182599, objectId=86501825990a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86501825990a, replyNumber=0, likeNumber=65, createdTime=2019-11-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86501825990a, moduleTitle=基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86501825990a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

LEO pharma的IL-13单抗在III期特应性皮炎临床研究中达到实验终点

2019-12-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant

2019-12-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果

2019-12-13

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功

2019-12-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

IMbrave 150：III期研究显示肝癌迎来治愈希望

2019-12-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira

2019-12-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功

2019-12-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Ardelyx的实验性药物Tenapanor达到了高磷血症的第二个III期研究的主要目标

2019-12-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点

2019-12-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：Satralizumab治疗视神经脊髓炎谱系疾病的SAkuraSky III期研究取得喜人结果

2019-12-02

智智灵药 (审核中...)

前往app查看评论内容

#III期#

急性脑缺血性中风治疗：sovateltide（PMZ-1620）的III期关键性研究已经开始

2019-11-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

第68届ASTMH年会：登革热候选疫苗关键III期试验的18个月数据

2019-11-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点

2019-11-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上

2019-11-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功

2019-11-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

2019-11-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

吉利德的Vemlidy在III期研究中，可显著降低慢性乙型肝炎感染患者肝细胞癌的发生

2019-11-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

阿斯利康宣布其干扰素受体靶向单抗anifrolumab治疗系统性红斑狼疮的阳性III期结果

2019-11-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床

2019-11-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

基于阳性III期结果，EMA已接受将Bratovi和Mektovi联合用于转移性结直肠癌治疗的申请

2019-11-09

科室
- - 订阅+
  - 更多科室
工具
服务